Evidence map›Paper›PMID 9030614›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience1997

Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes.

Y Feng, C A Gutekunst, D E Eberhart, H Yi, S T Warren, S M Hersch

3 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 221 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06480968 phase1completednot on this mapstarted 2023, after this paper: background citation

Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2023 to 2024Enrolled76ConditionsFragile X SyndromeArmsCTH120, Placebo
NCT06957054 completednot on this mapstarted 2024, after this paper: background citation

Assessment of Neural Biomarkers in Adult Subjects With Fragile X Syndrome and Typically Developing Subjects

TypeobservationalSponsorConnecta Therapeutics, S.L.Ran2024 to 2025Enrolled20ConditionsFragile X Syndrome (FXS), Neurotypical AdultsArmsAny
NCT07654114 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Safety, Tolerability, and Effectiveness of CTH120 in Adult Males With Fragile X Syndrome

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2026 to 2027Enrolled30ConditionsFragile X Syndrome (FXS), Fragile X SyndromeArmsCTH120, CTH120 placebo hard capsules
3 · Its place in the literature

Who cites it

221 citing papers in PubMed, 1 synthesis or guideline pooled it, 534 citations in OpenAlex.

  1. Guideline
  2. Altered cerebral protein synthesis in fragile X syndrome: studies in human subjects and knockout mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2013
    Trial
  3. bioRxiv : the preprint server for biology · 2026
    Article
  4. The enigma of nuclear FMRP: facts and myths.Frontiers in cell and developmental biology · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. State-of-the-art therapies for fragile X syndrome.Developmental medicine and child neurology · 2024
    Review
  9. Article
  10. The intersection of sleep and synaptic translation in synaptic plasticity deficits in neurodevelopmental disorders.Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology · 2024
    Review
  11. The Role of NRF2 in Trinucleotide Repeat Expansion Disorders.Antioxidants (Basel, Switzerland) · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Y FengHoward Hughes Medical Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
C A Gutekunst
D E Eberhart
H Yi
S T Warren
S M Hersch
Emory University · USHoward Hughes Medical Institute · USLaboratoire de Biochimie · FR

Funding

MOLECULAR CLONING OF THE FRAGILE X SITER01HD020521 · NICHD · EMORY UNIVERSITY · PI WARREN, STEPHEN T. · 1986 to 2011
$2.8M
MOLECULAR CLONING OF THE FRAGILE X SITER37HD020521 · NICHD · EMORY UNIVERSITY · PI WARREN, STEPHEN T. · 1996 to 2005
$1.7M
ANATOMIC AND MOLECULAR PATHOLOGY IN HUNTINGTON'S DISEASEK08NS001624 · NINDS · EMORY UNIVERSITY · PI HERSCH, STEVEN M · 1993 to 1997
–
NICHD NIH HHS HD20521NICHD NIH HHS R01 HD020521NICHD NIH HHS R37 HD020521NINDS NIH HHS NS01624
6 · The paper itself

Abstract

Fragile X syndrome, a leading cause of inherited mental retardation, is attributable to the unstable expansion of a CGG-repeat within the FMR1 gene that results in the absence of the encoded protein. The fragile X mental retardation protein (FMRP) is a ribosome-associated RNA-binding protein of uncertain function that contains nuclear localization and export signals. We show here detailed cellular localization studies using both biochemical and immunocytochemical approaches. FMRP was highly expressed in neurons but not glia throughout the rat brain, as detected by light microscopy. Although certain structures, such as hippocampus, revealed a strong signal, the regional variation in staining intensity appeared to be related to neuron size and density. In human cell lines and mouse brain, FMRP co-fractionated primarily with polysomes and rough endoplasmic reticulum. Ultrastructural studies in rat brain revealed high levels of FMRP immunoreactivity in neuronal perikarya, where it is concentrated in regions rich in ribosomes, particularly near or between rough endoplasmic reticulum cisternae. Immunogold studies also provided evidence of nucleocytoplasmic shuttling of FMRP, which was localized in neuronal nucleoplasm and within nuclear pores. Moreover, labeling was observed in large- and small-caliber dendrites, in dendritic branch points, at the origins of spine necks, and in spine heads, all known locations of neuronal polysomes. Dendritic localization, which was confirmed by co-fractionation of FMRP with synaptosomal ribosomes, suggests a possible role of FMRP in the translation of proteins involved in dendritic structure or function and relevant for the mental retardation occurring in fragile X syndrome.

Indexed as

RNA-Binding ProteinsAnimalsCell LineCell NucleusCerebral CortexCytoplasmDendritesEndoplasmic Reticulum, RoughFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansImmunoenzyme TechniquesImmunohistochemistryMaleMiceNerve Tissue ProteinsFMR1 protein, humanFmr1 protein, mouseFmr1 protein, ratFragile X Messenger Ribonucleoprotein 1Nerve Tissue ProteinsRNA-Binding Proteins

Identifiers

PMID9030614
PMCPMC6573369
OpenAlexW2132943956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.